Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients

• DOI: 10.1007/s12185-020-02836-7
• Publication Date: 2020-02-13T14:02:41Z
• Authors: Xuan Zhou; Meihong Zheng; Qien Wang; Jiye Aa; Bei Cao; Juan Li
• Keywords: Adult; Aged, 80 and over; Male; Risk; 0303 health sciences; Taurine; Lysine; Middle Aged; Prognosis; 3. Good health; Leukemia, Myeloid, Acute; Young Adult; 03 medical and health sciences; Mutation; Biomarkers, Tumor; Humans; Metabolomics; Female; Aged

There is an ongoing search for potential biomarkers for acute myeloid leukemia (AML) patients using metabolic analysis. However, only few studies to date have focused on bone marrow samples or a specific subtype of AML. In the present study, we used gas chromatography time-of-flight mass spectrometry of plasma and bone marrow supernatants to compare the metabolic characteristics of patients with AML with maturation (AML-M2). This approach identified significantly altered metabolites. We next performed pathway analysis and determined relative mRNA expression by qRT-PCR. Our results show that lysine, methionine and serine were significantly decreased in AML-M2 patients compared with healthy control. Moreover, plasma abundance of lysine was negatively associated with patients' risk stratification. Taurine had higher plasma abundance in AML-M2 patients and plasma level of taurine was positively related with AML-M2 risk status, while the expression level of taurine transporter showed a negative correlation. Receiver operating characteristic curve analysis showed these four metabolites had high diagnostic value with lysine showing the highest sensitivity and specificity. These results suggest that plasma abundances of lysine and taurine may serve as potential metabolic biomarkers for the prognosis of patients with AML-M2.